Showing promise in the arena of weight management therapy, retatrutide is a unique approach. Different from many current medications, retatrutide operates as a dual agonist, at once affecting both GLP-like peptide-1 (GLP-1) and glucose-dependent insulinotropic substance (GIP) binding sites. The dual engagement promotes multiple advantageous effects